WELCOME TO EPHI-IRB

Submit a protocol, Track progress, and get certified consent for your study.

Get started

Verify Clearance Submit new protocol

Conduct your research with confidence

Follow the guidelines and prepare necessary documents before you submit a protocol

Protocol Submission Process

Take an easy steps for the Protocol Submission Process.

Sign Up to the system

Make sure that you have correct access right to submit your protocol to our system. Update your personal profile, Yous CV s and directorates accordingly.

Submit Your protocol

Read the protocol submission guidelines and prepare your documents required for the submission. Send the application accordingly and wait for the response.

Track the progress

Once your protocol received by our IRB Secretariat, follow the protocol status and the progress untill your application get an approval clearance and archived to our system.

EPHI IRB Protocol Submission Guideline and Procedure

Institutional Review Board (IRB) — Scientific and Ethical Review Office (SERO)

Overview and scope

This page provides a complete, practical guide for researchers, students, and collaborators submitting human subjects research protocols to the Ethiopian Public Health Institute (EPHI) Institutional Review Board (IRB) through the Scientific and Ethical Review Office (SERO). It covers preparation, submission, review, and post-approval obligations.

Note: Details such as timelines, templates, and system links may vary across departments or studies. Customize placeholders in this guide to match the current EPHI/SERO requirements and your study’s specifics.

Audience: Principal Investigators (PIs), Co-investigators, Students, Data Managers, and Study Coordinators

Eligibility and when IRB review is needed

Studies requiring IRB review

  • Research involving human participants, identifiable biospecimens, or personal data
  • Interventional or observational public health studies conducted under EPHI auspices
  • Secondary use of existing data if it is identifiable or can be re-identified
  • International collaborations involving data or sample transfer

Possible exemptions (confirm with IRB)

  • De-identified datasets with no re-identification risk
  • Quality improvement activities without research intent
  • Publicly available data with no privacy concerns

Always request an exemption determination from IRB; do not self-exempt.

Required documents and templates

Prepare the following documents. Use EPHI’s latest templates where applicable.

Core protocol package

  • Protocol document (objectives, methods, risk/benefit, consent process, data plan)
  • Investigator CVs and roles (PI, Co-I, coordinator)
  • Consent forms in relevant local languages; assent forms for minors
  • Data management plan (security, retention, sharing, governance)
  • Sample management plan (collection, storage, chain-of-custody)
  • Community engagement plan, if applicable

Supporting materials

  • Questionnaires, interview guides, case report forms
  • Recruitment materials (flyers, scripts, radio messaging)
  • Letters of support and site permissions
  • Collaboration/MoU agreements; data/material transfer agreements (DTA/MTA)
  • Budget and funding details; conflict of interest disclosure

Compliance and approvals

  • National and institutional approvals relevant to the study
  • Ethical compliance statements (vulnerable populations, compensation)
  • Safety monitoring plan (DSMB/monitoring, if interventional)
Tip: Name files clearly and consistently. Example: PI_Lastname_Protocol_v1.2_2025-12-13.pdf, Consent_Amharic_v1.0.pdf, DMP_v0.9.docx.

Submission process and system access

Before you submit

  • Confirm study classification (Exempt, Expedited, Full) with SERO/IRB coordinator.
  • Complete required trainings (e.g., human subjects protection). Attach certificates.
  • Ensure all documents are final, consistent across languages, and signed where needed.

How to submit

  1. Create or access your investigator profile in the IRB submission system or designated channel.
  2. Start a new submission, select “New Protocol,” and enter study metadata (title, PI, sites, populations).
  3. Upload all required files. Verify readability and correct versions.
  4. Complete declarations (risk level, data handling, compensation, vulnerable groups).
  5. Submit and record the protocol reference number for tracking.

Initial screening

The IRB office performs an administrative pre-review to check completeness and eligibility. You may receive a request for clarifications or missing items. Respond promptly to avoid delays.

Stage What happens Investigator action
Pre-review Completeness check; classification confirmation Provide any missing documents or corrections
Assigned review Reviewer(s) and meeting date scheduled Be available for clarification; prepare presentations if requested
Decision Outcome letter issued with conditions or revisions Address conditions; submit revised documents

Review pathways, timelines, and outcomes

Review categories

  • Exempt review: minimal risk, specific criteria
  • Expedited review: minimal risk, designated procedures
  • Full board review: greater than minimal risk or special populations

Confirm category with the IRB coordinator during pre-review.

Indicative timelines

  • Pre-review: ~5–10 business days
  • Expedited review: ~10–20 business days
  • Full board: scheduled meeting; decision typically within ~30–45 days

Actual timelines depend on completeness, complexity, and meeting schedules.

Possible outcomes

  • Approval: Authorized to begin per approved documents.
  • Conditional approval: Minor changes required before activation.
  • Revise and resubmit: Substantive changes needed.
  • Not approved: Ethical or methodological concerns not resolved.

Investigator responsibilities

Conduct and compliance

  • Adhere to approved protocol, consent, and data plans.
  • Train all team members; document delegation of duties.
  • Maintain secure records and audit trails.
  • Obtain renewed consent if procedures change materially.

Communication

  • Report adverse events, unanticipated problems, or deviations promptly.
  • Submit amendments before implementing changes.
  • Respond to IRB queries within requested timelines.

Documentation

  • Keep a regulatory binder: approvals, versions, logs, training, correspondence.
  • Version control: label documents with version and date.
  • Retention: store data/specimens per approved durations.

Amendments and continuing review

Amendments

Submit amendments for any change impacting consent, risk, procedures, populations, data sharing, or sites. Provide a summary of changes, tracked revisions, and updated materials. Do not implement changes before IRB approval unless required for immediate safety; report such deviations promptly.

Continuing review / renewal

  • Track approval expiry dates and initiate renewal at least 30 days in advance.
  • Provide progress reports, enrollment numbers, adverse events summary, and any updated plans.
  • If closing, submit a study closure report and ensure proper data/specimen disposition.

Reporting adverse events and deviations

What to report

  • Serious adverse events (SAEs) and unanticipated problems involving risks to participants
  • Protocol deviations or violations
  • Data breaches, confidentiality incidents, or specimen mislabeling

How and when

  • Use the designated IRB reporting form or portal.
  • Report SAEs promptly per IRB/DSMB requirements.
  • Provide corrective and preventive action (CAPA) plans.

Data protection and sample handling

Data protection

  • Apply least-privilege access; role-based permissions.
  • Encrypt data at rest and in transit.
  • Use secure, approved platforms for storage and analysis.
  • De-identify or pseudonymize where appropriate; manage keys securely.
  • Define sharing terms in DMP, DTA/MTA, and consent.

Sample handling

  • Document chain-of-custody and labeling standards.
  • Store per biosafety and biobank requirements.
  • Track inventory and movements; reconcile regularly.
  • Align export/import with regulatory approvals and MTAs.
Reminder: Align your DMP and sample plan with consent language and regulatory approvals.